Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2021 | Highlights from the immunotherapy in CLL session

David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, shares the highlights from the immunotherapy session at iwCLL 2021. Dr Maloney firstly discusses the pros and cons of allogeneic stem cell transplantation and chimeric antigen receptor T-cell therapy (CAR-T) for chronic lymphocytic leukemia (CLL), arguing that CAR-T therapy is more efficacious than allogeneic stem cell transplantation. Dr Maloney then highlights the use of agents including BTK inhibitors and lenalidomide to modulate T-cell responses and comments on the findings of a clinical trial (NCT01865617) investigating CD19-directed autologous CAR-T therapy in combination with ibrutinib for relapsed/refractory patients with CLL. Finally, Dr Maloney presents data showing that CLL cells treated with CAR-T therapy are able to downregulate CD19 expression, suggesting that strategies to increase CD19 persistence of these cells might be useful. This interview took place at the 19th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held virtually in 2021.

Disclosures

David Maloney, MD, PhD, has received honoraria for consultancy work from BMS, Incyte, Juno Therapeutics, Kite, Mustang Bio, Novartis and Umoja; has received institutional research funding, including salary support, from Kite Pharma, Juno Therapeutics and Celgene; has the rights to royalties from Fred Hutch for patents licensed to Juno Therapeutics/BMSA, has stock options in A2 Biotherapeutics and Navan Technologies; is a member of the scientific advisory boards for A2 Biotherapeutics, Navan Technologies and Chimeric Therapeutics; and is Chair of the Lymphoma Steering Committee at Genentech.